Centessa Pharmaceuticals — Investor Presentation (September 2022)
27 slides from Centessa Pharmaceuticals's investor presentation, Sep 12, 2022
Slide 1: Corporate Overview: Asset-Centric. Patient-Centric.
Corporate Overview Asset-Centric. Patient-Centric.
Slide 2: Disclaimer and forward-looking statements
This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv
Slide 3: Discovering and developing medicines that are truly transformational for patients
Discovering and developing medicines that are truly transformational for patients Multiple potential blockbuster assets with clinical readouts anticipated over next two years Cash runway into 2026 enables clinical proof of concept readouts across portfolio World-class R&D team 3Note: $484.2 million
Slide 4: A transformational pharmaceutical company fueling an innovative pipeline
DIFFERENTIATION We are a transformational pharmaceutical company fueling an innovative pipeline 4 Lead Assets Disease Estimated Market Size* SerpinPC Hemophilia B $2B+1 LB101 Solid Tumors $10B1 MGX292 Pulmonary Arterial Hypertension (PAH) $6B1 OX2R Agonists Narcolepsy (NT1) $2B+1 MULTIPLE PATHWAYS T
Slide 5: Cash runway into 2026 enables clinical proof of concept readouts across pipeline
PRE-CLINICAL PHASE 1 PHASE 2 REGISTRATIONAL SerpinPC in Hemophilia (Hemophilia B Registrational Trial) LB101 in Solid Tumors MGX292 in Pulmonary Arterial Hypertension (PAH) OX2R Agonists in Narcolepsy (NT1) CBS001 in Inflammatory/ Fibrotic Diseases CBS004 in Systemic Sclerosis, Lupus Erythematosus 2
Slide 6: Team with deep R&D experience focused on execution
LEADERSHIP Team with deep R&D experience focused on execution 6 THOMAS TEMPLEMAN PhD Chief Technology Officer DAVID CHAO PhD Chief Administrative Officer TIA BUSH Chief Quality Officer SAURABH SAHA MD PhD Chief Executive Officer ANTOINE YVER MD MSc EVP & Chairman of Development DAVID GRAINGER PhD Ch
Slide 7: SerpinPC in Hemophilia
SerpinPC in Hemophilia YK CENTESSA
Slide 8: SerpinPC: Potential transformative therapy in hemophilia
SerpinPC: Potential transformative therapy in hemophilia 8 Novel MoA; Non-factor approach Significant reduction in bleeding2 Potential best-in- class safety profile: No thrombosis observed2 Convenient subcutaneous dosing Inhibitor of APC designed to prevent and reduce bleeds without risk of thrombos
Slide 9: SerpinPC is believed to have a unique MoA supported by human genetics
SerpinPC is believed to have a unique MoA supported by human genetics 9 Primary APC is the target of SerpinPC All beds Spontaneous joint bleeds • Human genetic target validation • Engineered to specifically inhibit APC • Inhibition of APC increases thrombin • Feedback loop prevents excess thrombin g
Slide 10: Phase 2a Study: SerpinPC showed significant reductions in bleeding rates
Phase 2a Study: SerpinPC showed significant reductions in bleeding rates 10 One moderate skin reaction led to withdrawal of a subject with history of a skin disorder. Two subjects with ADAs, with no apparent impact on ABRs. No other SerpinPC-related AEs. ABR is annualized bleeding rate. Six-month up
Slide 11: Phase 2a Study: Individual observed ABRs for all bleeds and spontaneous joint bleeds
Phase 2a Study: Individual observed ABRs for all bleeds and spontaneous joint bleeds 11 All bleeds ABR Spontaneous joint bleeds ABR Six-month update of Phase 2a Study. ABR is annualized bleeding rate. 1. During second 12 weeks of exposure (as prespecified in the statistical analysis plan). Once mont
Slide 12: Phase 2a Study: Individual observed ABRs across dose cohorts
Phase 2a Study: Individual observed ABRs across dose cohorts 12Six-month update of Phase 2a Study. ABR is annualized bleeding rate. 1. During second 12 weeks of exposure (as prespecified in the statistical analysis plan). Once monthly injections. -60 -40 -20 0 20 40 60 0.3 mg/kg 1.2 mg/kg 0.6 mg/kg
Slide 13: Registrational study design for hemophilia B
13 1.2 mg/kg SC Q1W n=20 1.2 mg/kg SC Q2W n=20 1.2 mg/kg SC Q4W n=20 Part 1 (24 weeks) Randomized Dose Justification Phase Prophylaxis cohort: n=30 (HemB ≥15) 12-week observation period Part 2 (24 weeks) Efficacy/safety assessment Part 3 (24 weeks) Additional efficacy/safety data Subjects from Part
Slide 14: LB101 in Solid Tumors
LB101 in Solid Tumors 14
Slide 15: LB101: Potential first-in-class immunotherapy targeting solid tumors
LockBody “It’s all about the hinge” LB101:Potential first-in-class immunotherapy targeting solid tumors 15 Pioneering our novel LockBody® pharmacology IND submission planned for late 2022; Additional LockBody candidates expected in 2023 S T A T U S : Novel pharmacology focused on human IgG- derived
Slide 16: LB101: Designed to deliver anti-PD-L1 activity plus targeted anti-CD47 activity to the TME
LB101: Designed to optimally deliver anti-PD-L1 activity plus targeted anti-CD47 activity to the TME 16 Tumor Unlocking: IgG1 hinges susceptible to cleavage in diseased tissue by various natural processes Peripheral Stability: IgG1 hinges naturally resistant to cleavage in serum Constitutive Fabs: P
Slide 17: LB101 showed improved efficacy and durability over atezolizumab in a mouse model
LB101 showed improved efficacy and durability over atezolizumab in a difficult-to-treat mouse model while being well tolerated 17 In vivo: Systemically delivered LB101 exhibited significant tumor regression In vivo: LB101 was well tolerated with no weight loss Note: MC38 hPD-L1+ syngeneic model in m
Slide 18: LB101 shown to be safe and well tolerated in non-human primates
LB101 shown to be safe and well tolerated in non-human primates 18 In-vivo: LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates • Human IgG1-like PK • No adverse observations - No impact on any hematology (no anemia or thrombocytopenia) - No changes in pathology, clinical chemistry
Slide 19: MGX292 in Pulmonary Arterial Hypertension
19 MGX292 in Pulmonary Arterial Hypertension
Slide 20: MGX292: Potential for disease reversal in patients with PAH
20 MGX292: Potential for disease reversal in patients with PAH Novel MoA with potential for disease reversal Designed to directly restore BMP9 signaling genetically missing or deficient in PAH and avoid undesired bone formation In vivo data demonstrated reversal of lung vascular pathology Protein-en
Slide 21: Preclinical Data: MGX292 demonstrated dose-dependent reversal of lung vascular pathology
Preclinical Data: MGX292 demonstrated dose- dependent reversal of established lung vascular pathology in Sugen-hypoxia rat model 1. MGX292 treatment was given daily for 4 weeks; 2. Red arrows depict vascular lesions MGX2921 reversed neointimal lesions in Sugen-hypoxia rat model of severe PAH 0 5 10
Slide 22: OX2R Agonists in NT1
OX2R Agonists in NT1 22
Slide 23: OX2R Agonists: Potential to change the standard of care for narcolepsy
Highly validated human genetic target Clinical proof of concept (PoC) for efficacy in NT1 and in other sleep/wake disorders3 23 OX2R Agonists: Potential to change the standard of care for narcolepsy High unmet need EDS is excessive daytime sleepiness. 1. Evaluate Pharma 2021. 2. Maski K, et al. J Cl
Slide 24: Structure-based drug design has enabled discovery of OX2R agonists
Structure-based drug design has enabled the discovery of OX2R agonists with potential as replacement therapy for NT1 The newest compounds have demonstrated sub-nanomolar potency in in vitro assays * Example X-ray structure of OX2R with small molecule orexin agonist (shown in purple) Example Cryo-EM
Slide 25: Novel OX2R agonists increase wakefulness in WT and NT1 mice
Novel OX2R agonists increase wakefulness in WT and NT1 mice Note: Wakefulness detected by piezoelectric monitoring, which is a rapid, non-invasive method for classifying sleep and wakefulness by unsupervised machine learning Exemplar small molecule agonists Exemplar peptide agonist 25 NT1 Mouse Mode
Slide 26: Centessa is fueling multiple pathways to value creation
Centessa is fueling multiple pathways to value creation 26 Multiple potential blockbuster assets with clinical readouts anticipated over next two years Cash runway into 2026 enables clinical proof of concept readouts across portfolio World-class R&D team Note: $484.2 million in cash and cash equival
Slide 27: Centessa Pharmaceuticals
<< CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals — Investor Presentation (September 2022) on 6ix